GLP-1 Class
Retatrutide
COA VERIFIEDNEW

Retatrutide

C₂₂₇H₃₄₈N₄₈O₆₈S

GLP-1 Class
HPLC PURITY98.3%

Novel triple agonist (GIP/GLP-1/glucagon) peptide under investigation for metabolic research.

Molecular Weight
5100.8 g/mol
Appearance
White lyophilized powder
Storage
Store at -20°C. Protect from light and moisture.

Select Size

Quantity

1
$89.99

Retatrutide (LY-3437943) is a novel triple-acting receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. This tri-agonist approach represents a new paradigm in metabolic research. Preclinical and clinical studies have shown significant effects on body weight reduction and glycemic control, surpassing single and dual agonist compounds. It is currently one of the most studied peptides in the metabolic research field.

Related Compounds

Semaglutide
COA VERIFIEDPOPULARNEW

GLP-1 Class

Semaglutide

C₁₈₇H₂₉₁N₄₅O₅₉

GLP-1 receptor agonist extensively studied for metabolic research and glucose homeostasis.

HPLC PURITY98.5%
From $79.99
Tirzepatide
COA VERIFIEDPOPULAR

GLP-1 Class

Tirzepatide

C₂₂₅H₃₄₈N₄₈O₆₈

Dual GIP/GLP-1 receptor agonist studied for glucose metabolism and body composition research.

HPLC PURITY98.6%
From $99.99

Research Use Only — Legal Disclaimer

All products sold by Halo Peptides are strictly intended for in-vitro research, laboratory use, and scientific investigation only. They are not intended for human consumption, veterinary use, diagnostic purposes, or any therapeutic application. By browsing this website and purchasing any product, you acknowledge and agree that you are a qualified researcher and will use all compounds in compliance with applicable local, national, and international laws and regulations.